Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has earned a consensus recommendation of “Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $9.31.

TRVI has been the subject of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Thursday, December 12th. D. Boral Capital reissued a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright boosted their target price on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research report on Thursday, December 12th.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently made changes to their positions in TRVI. Point72 Asset Management L.P. bought a new stake in shares of Trevi Therapeutics in the 4th quarter worth about $17,099,000. Frazier Life Sciences Management L.P. grew its holdings in Trevi Therapeutics by 44.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Woodline Partners LP grew its holdings in Trevi Therapeutics by 429.9% during the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock worth $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Trevi Therapeutics during the 4th quarter worth about $10,300,000. Finally, Acorn Capital Advisors LLC bought a new stake in Trevi Therapeutics during the 4th quarter worth about $8,244,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.80 on Friday. The firm has a market cap of $368.98 million, a PE ratio of -10.91 and a beta of 0.88. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $4.89. The firm’s 50 day moving average price is $4.06 and its 200 day moving average price is $3.37.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.